Browsing by Author "Bradford, Ni' Ja D."
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item The effects of esmolol on the control of coronary blood flow and myocardial oxygen supply-demand balance in sepsis(2024-03-21) Digilio, Michaela; Warne, Cooper; Heard, Michael; Tucker, Selina; Essajee, Sal; Bradford, Ni' Ja D.; Hodge, Lisa; Tune, Johnathan; Dick, GregoryPurpose: Sepsis is an acute organ dysfunction secondary to infection that results in tachycardia, tachypnea, fever, decreased blood pressure, and lactic acidosis. This results in an overall myocardial oxygen supply-demand imbalance leading to cardiac dysfunction and ultimately death. The current treatment for sepsis is antibiotic therapy, vasopressors, and fluid therapy. However, this regimen does not address the tachycardia that leads to cardiovascular decompensation. Beta-blocker therapy addresses this myocardial oxygen supply-demand imbalance and is expected to promote survival in sepsis. We hypothesize that treatment with beta-blocker therapy during acute sepsis will address the myocardial oxygen supply-demand imbalance to maintain coronary perfusion pressure, improve myocardial oxygen delivery, and promote survival. Methods: Female and male Yorkshire pigs were used as the animal model for this project. Pigs were anesthetized, intubated, and a rectal thermometer and oximeter were placed. Catheters placed in ear vein, great cardiac vein, femoral artery, and bilateral femoral veins. Pressure transducer placed in the femoral artery. A transonic flow transducer placed around the left anterior descending artery. After instrumentation, baseline values were collected. Then, infusion with Escherichia coli lipopolysaccharide (LPS) at 10 µg/kg over the course of 2 hours was used to induce sepsis. LPS was infused via the femoral vein at a rate of 0.5mL/min. After 2 hours, intervention began depending on the treatment group. Intervention lasted 4 hours. Experiment groups included Sham (without LPS, fluids, norepinephrine (NE), or esmolol), Control (with LPS, no fluids, NE, or esmolol), Standard (with LPS, fluids, and NE), and Experimental (with LPS, fluids, NE and esmolol). Doses: LPS 10 µg/kg, esmolol escalating from 100mg/hr, and NE escalating from 0.4 µg/kg/min. Goals during the intervention included keeping the mean arterial pressure (MAP) above 65mmHg and heart rate below 100. Results: All control pigs died during the 4-hour follow-up. 1 out of 3 standard treatment pigs survived. All esmolol-treated pigs survived. The esmolol group had better MAP, coronary blood flow, myocardial oxygen delivery, and oxygen extraction than the standard treatment group. Conclusion: Esmolol improves survival, coronary perfusion pressure, and myocardial oxygen delivery. This data provides support for our hypothesis and the clinical use of esmolol in sepsis.Item The effects of esmolol on the control of coronary blood flow and myocardial oxygen supply-demand balance in sepsis(2023-05) Bradford, Ni' Ja D.; Hodge, Lisa M.; Dick, Gregory M.; Tune, Johnathan D.; Mallet, Robert T.Purpose: Sepsis is life-threatening acute organ dysfunction secondary to infection and a major cause of morbidity and mortality in critically ill patients. Sepsis accounts for ~5% of the U.S.'s hospital costs. Hallmarks of sepsis include cognitive impairment, elevated heart rate, low blood pressure, metabolic acidosis, immune dysfunction, respiratory dysfunction, capillary leakiness, thermal dysregulation, multiple organ dysfunction, and shock. Currently, the standard treatment of care includes fluid therapy, antibiotics, and vasopressors; however, these treatments are not optimal, as the mortality rate approaches 26%. The current standard of care for sepsis does not address increases in heart rate, but recent trials show that esmolol (a short-acting, highly selective beta blocker) reduces mortality. Esmolol effectively controls heart rate without increasing adverse effects. Importantly, the mechanisms of action of esmolol during sepsis are not well understood, particularly regarding the coronary circulation. The purpose of this study is to investigate the effects of esmolol on the control of coronary blood flow and myocardial oxygen supply-demand balance in sepsis. We chose the pig as a model because they closely resemble humans in terms of heart rate, blood pressure, and alveolar ventilation, making it a robust large animal model for translational research. We hypothesize that treatment with esmolol during acute sepsis will increase survival, maintain coronary perfusion pressure, and improve myocardial oxygen delivery. We also predict that esmolol will improve mixed venous oxygen saturation and attenuate lactic acidosis. The following specific aim will be addressed: Identify coronary vascular mechanisms underlying the protective effect of esmolol during acute sepsis. Methods: Yorkshire pigs (61.3 ± 9 kg, n=11) were used. Our model of acute sepsis is an anesthetized, open-chest pig instrumented for measurements of coronary blood flow, arterial pressure, and blood sampling (arterial, mixed venous, and coronary venous). Lipopolysaccharide (LPS; 10 μg/kg) was infused intravenously over 2 h. At the end of LPS infusion, medical intervention was started and lasted 4 h. Three medical interventions were compared: 1) no treatment 2) standard treatment of saline plus norepinephrine (NE, to maintain blood pressure) and 3) experimental treatment of the combination of saline, NE, and esmolol (to maintain blood pressure and reduce heart rate). A sham group where no LPS or treatment was given was compared to the other three medical interventions to account for values affected by the anesthesia. Hemodynamic variables were measured constantly, while blood samples were taken every 30 min. Results: Only the sham and the experimental group treated with esmolol in addition to the standard treatment had a 100% survival rate, whereas the standard treatment group had a 75% survival rate. The control group had a 0% survival rate. The addition of esmolol to standard treatment effectively reduced heart rate in comparison to every other treatment group. Additionally, the addition of esmolol was better able to maintain mean arterial pressure, coronary blood flow, myocardial oxygen delivery, and extraction closer to baseline than the standard treatment or the control groups. Indicating that esmolol improved myocardial oxygen supply and demand balance. Furthermore, esmolol attenuated the reduction of coronary venous PO2 in septic patients. However, esmolol did not attenuate the reduction of mixed venous PO2 or elevated lactic acid in the porcine sepsis model. Conclusions: The outcomes of the study provide greater insight into the coronary vascular mechanisms of esmolol treatment that promote survival in sepsis. The impact of our studies will be a more solid mechanistic foundation upon which to design clinical trials of esmolol patients with sepsis.